Tower Research Capital LLC (Trc) Krystal Biotech, Inc. Transaction History

Tower Research Capital LLC (Trc)

$4.87 Billion
Q4 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,999 shares of KRYS stock, worth $1.21 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

6,999

Previous 87 7944.83%

Holding current value

$1.21 Million

Previous $15,000 7206.67%

% of portfolio

0.02%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$156.64 - $199.61 $1.08 Million - $1.38 Million	6,912 Added 7944.83%	6,999 $1.1 Million
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $369,490 - $451,890	-2,115 Reduced 96.05%	87 $15,000
Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $86,512 - $103,756	565 Added 34.51%	2,202 $404,000
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $41,151 - $68,332	381 Added 30.33%	1,637 $291,000
Q4 2023 Feb 13, 2024	SELL	$96.0 - $128.29 $33,600 - $44,901	-350 Reduced 21.79%	1,256 $155,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $98,852 - $118,630	911 Added 131.08%	1,606 $186,000
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $20,483 - $34,013	-261 Reduced 27.3%	695 $81,000
Q1 2023 May 09, 2023	BUY	$72.39 - $84.27 $41,334 - $48,118	571 Added 148.31%	956 $77,000
Q4 2022 Feb 10, 2023	SELL	$63.14 - $79.9 $195,228 - $247,050	-3,092 Reduced 88.93%	385 $31,000
Q3 2022 Nov 10, 2022	BUY	$64.85 - $82.4 $46,043 - $58,504	710 Added 25.66%	3,477 $242,000
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $17,565 - $26,375	-359 Reduced 11.48%	2,767 $181,000
Q1 2022 May 12, 2022	SELL	$51.99 - $72.11 $128,571 - $178,328	-2,473 Reduced 44.17%	3,126 $208,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $126,954 - $281,397	3,189 Added 132.32%	5,599 $391,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $29,021 - $40,047	558 Added 30.13%	2,410 $126,000
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $45,610 - $60,055	734 Added 65.65%	1,852 $126,000
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $28,165 - $40,508	474 Added 73.6%	1,118 $87,000
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $13,045 - $19,702	321 Added 99.38%	644 $39,000
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $126,458 - $162,393	-3,349 Reduced 91.2%	323 $14,000
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $135,974 - $220,320	3,672 New	3,672 $152,000
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $41,323 - $77,455	-1,180 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$33.17 - $65.23 $16,485 - $32,419	497 Added 72.77%	1,180 $65,000
Q3 2019 Nov 05, 2019	SELL	$34.72 - $51.3 $38,608 - $57,045	-1,112 Reduced 61.95%	683 $23,000
Q2 2019 Aug 13, 2019	BUY	$27.2 - $41.2 $48,824 - $73,954	1,795 New	1,795 $72,000
Q1 2019 May 14, 2019	SELL	$19.86 - $32.9 $22,640 - $37,506	-1,140 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$15.03 - $25.38 $22,349 - $37,740	-1,487 Reduced 56.6%	1,140 $24,000
Q3 2018 Nov 13, 2018	BUY	$14.43 - $21.0 $37,907 - $55,167	2,627 New	2,627 $46,000

Others Institutions Holding KRYS

# of Institutions

300

Shares Held

24.3M

Call Options Held

388K

Put Options Held

233K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.45B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Krystal Biotech, Inc. Transaction History